1.Performance of the curriculum for communication skills for breaking bad news: Evaluation with Common Achievement Tests OSCE and advanced OSCE
Naoko IWASAKI ; Hikaru NAGAHARA ; Masanao TERAMURA ; Noriko KOJIMAHARA ; Masatoshi KAWANA ; Naomi HIZUKA ; Toshimasa YOSHIOKA ; Makiko OSAWA ; Keiko SHIRATORI
Medical Education 2010;41(2):103-109
Skills for breaking bad news (BBN) at the medical interview station were evaluated with the advanced objective structured clinical examination (OSCE). To clarify performances at this station, we compared the scores at this station with those of the Common Achievement Tests OSCE controlled by the Common Achievements Test Organization (CATO). The subjects were a group of students tested at an interval of 1 year 4 months during their clinical clerkships.1) Raters (mostly postdoctorate fellows) played simulated patients after they had been trained to ensure standardization.2) Students who had high scores for BBN skills on the advanced OSCE also had high scores for both the behavior part and the knowledge part of the total evaluation.3) In contrast, students who had high scores for BBN skills on the advanced OSCE did not always have high scores on the Common Achievement Tests OSCE, suggesting the importance of clinical clerkships between these 2 OSCEs.
2.Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report
Miki KOROKU ; Teppei OMORI ; Harutaka KAMBAYASHI ; Shun MURASUGI ; Tomoko KURIYAMA ; Yuichi IKARASHI ; Maria YONEZAWA ; Ken ARIMURA ; Kazunori KARASAWA ; Norio HANAFUSA ; Masatoshi KAWANA ; Katsutoshi TOKUSHIGE
Intestinal Research 2022;20(1):150-155
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.